Immunotherapy engagement in pancreatic adenocarcinoma: Provisional results of iLSTA study- Durvalumab, LSTA1 (certepetide), gemcitabine, and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma.

被引：0
|
作者：
Dean, Andrew Peter
Johansson, Mikael
Yusoff, Ian
Rao, Samarth
Sparrow, Susan
Kumarasinghe, Priyanthi
Navadgi, Suresh
Watanabe, Yuki
Webber, Laurence
Grew, Jenny
Fitzgerald, Shane
Comito, Olivia Rose
机构：
[1] St John God Subiaco Hosp, Subiaco, Australia
[2] Dept Upper GI Surg, Nedlands, Australia
[3] Sir Charles Gairdner Hosp, Nedlands, Australia
[4] Australian Clin Labs, Subiaco, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.746
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma
    Glen J. Weiss
    Lisa Blaydorn
    Julia Beck
    Kirsten Bornemann-Kolatzki
    Howard Urnovitz
    Ekkhard Schütz
    Vivek Khemka
    Investigational New Drugs, 2018, 36 : 96 - 102
  • [42] PANOVA-3: A phase III study of tumor treating fields with nab-paclitaxel and gemcitabine for front-line treatment of locally advanced pancreatic adenocarcinoma.
    Picozzi, Vincent J.
    Macarulla, Teresa
    Philip, A. Philip
    Becerra, Carlos R.
    Dragovich, Tomislav
    CANCER RESEARCH, 2021, 81 (22) : 35 - 36
  • [43] Sarcopenia Prognostic Value for Unresectable Pancreatic Ductal Adenocarcinoma Patients Treated With Gemcitabine Plus Nab-Paclitaxel
    Asama, Hiroyuki
    Ueno, Makoto
    Kobayashi, Satoshi
    Fukushima, Taito
    Kawano, Kuniyuki
    Sano, Yusuke
    Tanaka, Satoshi
    Nagashima, Shuhei
    Morimoto, Manabu
    Ohira, Hiromasa
    Maeda, Shin
    PANCREAS, 2022, 51 (02) : 148 - 152
  • [44] The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
    Dean, A.
    Das, A.
    McNulty, M.
    Travers, N.
    ANNALS OF ONCOLOGY, 2019, 30
  • [45] Gemcitabine, nab-paclitaxel, cisplatin, and anakinra (AGAP) treatment in patients with localized pancreatic ductal adenocarcinoma (PDAC)
    Becerra, Carlos
    Paulson, Andrew Scott
    Cavaness, Keith M.
    Celinski, Scott A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [46] NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice
    De Vita, Ferdinando
    Ventriglia, Jole
    Febbraro, Antonio
    Laterza, Maria Maddalena
    Fabozzi, Alessio
    Savastano, Beatrice
    Petrillo, Angelica
    Diana, Anna
    Giordano, Guido
    Troiani, Teresa
    Conzo, Giovanni
    Galizia, Gennaro
    Ciardiello, Fortunato
    Orditura, Michele
    BMC CANCER, 2016, 16
  • [47] A PHASE 1 STUDY OF GEMCITABINE / NAB-PACLITAXEL / S-1 (GAS) COMBINATION NEOADJUVANT CHEMOTHERAPY FOR PATIENTS WITH LOCALLY-ADVANCED PANCREATIC ADENOCARCINOMA
    Kondo, Naru
    Murakami, Yoshiaki
    Uemura, Kenichiro
    Sudo, Takeshi
    Hashimoto, Yasushi
    Nakagawa, Naoya
    Sueda, Taijiro
    GASTROENTEROLOGY, 2017, 152 (05) : S1250 - S1250
  • [48] Gemcitabine and nab-paclitaxel retreatment as a third-line therapy following second-line FOLFIRINOX for advanced pancreatic adenocarcinoma.
    Dean, Andrew Peter
    Das, Adarsh
    McNulty, Meabh
    Higgs, Domenic
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine in resected pancreatic ductal adenocarcinoma: A Chinese single institution.
    Yin, Zhuzeng
    Liu, Rong
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [50] Nab-paclitaxel plus S-1 as first-line treatment in patients with advanced pancreatic adenocarcinoma.
    Shi, Yan
    Yan, Huan
    Han, Quanli
    Nie, Yongkang
    Lv, Yao
    Wang, Zhikuan
    Dai, Guanghai
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345